US RE50,080 E1
Blood glucose control system
Firas El-Khatib, Allston, MA (US); Edward Damiano, Acton, MA (US); and Steven J. Russell, Lincoln, MA (US)
Assigned to Trustees of Boston University, Boston, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed by Trustees of Boston University, Boston, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed on Jan. 28, 2021, as Appl. No. 17/160,506.
Application 17/160,506 is a division of application No. 13/870,634, filed on Apr. 25, 2013, granted, now 9,833,570, issued on Dec. 5, 2017.
Application 13/870,634 is a continuation of application No. PCT/US2011/058688, filed on Oct. 31, 2011.
Application 17/160,506 is a reissue of application No. 15/380,516, filed on Dec. 15, 2016, granted, now 10,188,795, issued on Jan. 29, 2019.
Claims priority of provisional application 61/470,210, filed on Mar. 31, 2011.
Claims priority of provisional application 61/408,639, filed on Oct. 31, 2010.
Int. Cl. A61M 5/172 (2006.01); A61M 5/14 (2006.01); A61M 5/142 (2006.01); G16H 20/13 (2018.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/50 (2018.01); G16Z 99/00 (2019.01)
CPC A61M 5/1723 (2013.01) [A61M 5/14244 (2013.01); A61M 5/14248 (2013.01); G16H 20/13 (2018.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/50 (2018.01); G16Z 99/00 (2019.02); A61M 2005/1402 (2013.01); A61M 2005/14208 (2013.01); A61M 2202/07 (2013.01); A61M 2205/52 (2013.01); A61M 2230/201 (2013.01)] 16 Claims
OG exemplary drawing
 
7. A sensor-driven glucose control system according to claim 1, [ , comprising:
an insulin delivery device configured to receive an insulin dose control signal and operative in response to the insulin dose control signal to infuse priming doses of insulin to a subject; and
a controller configured and operative to generate the insulin dose control signal and send it to the insulin delivery device to:
(1) continually administer the priming doses of insulin at respective times, each priming dose being of a respective amount and having a prescribed interval of action;
(2) receive information regarding total amounts of insulin administered during the prescribed intervals of action, each total amount including an aggregation of total doses administered in response to a glucose level signal; and
(3) automatically adapt the amounts of the priming doses in response to a mathematical relationship, over respective periods each spanning multiple prescribed intervals of action, between the amounts of the priming doses and the total amounts of insulin administered during the prescribed intervals of action,
and ] further comprising a counter-regulatory agent delivery device [ configured to receive a counter-regulatory agent dose control signal and ] operative to infuse a counter-regulatory agent into the subject in response to a [ the ] counter-regulatory agent dose control signal, and wherein the controller is operative to generate the counter-regulatory agent dose control signal [ and send it to the counter-regulatory agent delivery device ] by performing a calculation generating (1) a raw dose control value based on the glucose level signal, and (2) the counter-regulatory agent dose control signal as a modification of the raw dose control value based on an estimation of an effect of insulin infused into the subject by the insulin delivery device.